1,534 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by Fifth Third Wealth Advisors LLC

Fifth Third Wealth Advisors LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,534 shares of the medical research company’s stock, valued at approximately $324,000.

A number of other large investors also recently bought and sold shares of IQV. International Assets Investment Management LLC purchased a new position in IQVIA during the fourth quarter worth approximately $13,759,000. abrdn plc lifted its position in IQVIA by 138.3% during the fourth quarter. abrdn plc now owns 108,151 shares of the medical research company’s stock worth $25,024,000 after buying an additional 62,776 shares in the last quarter. Signaturefd LLC increased its stake in IQVIA by 13.0% during the fourth quarter. Signaturefd LLC now owns 2,492 shares of the medical research company’s stock worth $577,000 after acquiring an additional 287 shares during the last quarter. CWM LLC increased its stake in IQVIA by 5.5% during the fourth quarter. CWM LLC now owns 3,980 shares of the medical research company’s stock worth $921,000 after acquiring an additional 207 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new stake in IQVIA during the fourth quarter worth $60,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 0.0 %

NYSE IQV traded up $0.06 during trading on Wednesday, reaching $247.00. 717,431 shares of the company’s stock were exchanged, compared to its average volume of 1,072,467. The stock has a market cap of $45.00 billion, a P/E ratio of 33.74, a price-to-earnings-growth ratio of 2.22 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company has a 50 day moving average price of $226.45 and a two-hundred day moving average price of $232.71. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the previous year, the business earned $2.22 EPS. IQVIA’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their target price on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Barclays lifted their price objective on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Morgan Stanley lifted their price objective on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Robert W. Baird lifted their price objective on IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a research note on Tuesday, July 23rd. Finally, Argus raised IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $265.67.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.